RT Journal Article
SR Electronic
T1 Development and Implementation of a scalable and versatile test for COVID-19 diagnostics in rural communities
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.01.21252679
DO 10.1101/2021.03.01.21252679
A1 Ceci, A.
A1 Muñoz-Ballester, C.
A1 Tegge, A.
A1 Brown, K.L.
A1 Umans, R.A.
A1 Michel, F.M.
A1 Patel, D.
A1 Tewari, B.
A1 Martin, J.
A1 Alcoreza, O.
A1 Maynard, T.
A1 Martinez-Martinez, D.
A1 Bordwine, P.
A1 Bissell, N.
A1 Friedlander, M.
A1 Sontheimer, H.
A1 Finkielstein, C.V.
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.01.21252679.abstract
AB Rapid and widespread testing of severe acute respiratory coronavirus 2 (SARS-CoV-2) is essential for an effective public health response aimed at containing and mitigating the coronavirus disease 2019 (COVID-19) pandemic. Successful health policy implementation relies on early identification of infected individuals and extensive contact tracing.However, rural communities, where resources for testing are sparse or simply absent, face distinctive challenges to achieving this success. Accordingly, we report the development of an academic, public land grant University laboratory-based detection assay for the identification of SARS-CoV-2 in samples from various clinical specimens that can be readily deployed in areas where access to testing is limited. The test, which is a quantitative reverse transcription polymerase chain reaction (RT-qPCR)-based procedure, was validated on samples provided by the state laboratory and submitted for FDA Emergency Use Authorization. Our test exhibits comparable sensitivity and exceeds specificity and inclusivity values compared to other molecular assays. Additionally, this test can be re-configured to meet supply chain shortages, modified for scale up demands, and is amenable to several clinical specimens. Test development also involved 3D engineering critical supplies and formulating a stable collection media that allowed samples to be transported for hours over a dispersed rural region without the need for a cold-chain. These two elements that were critical when shortages impacted testing and when personnel needed to reach areas that were geographically isolated from the testing center. Overall, using a robust, easy-to-adapt methodology, we show that an academic laboratory can supplement COVID-19 testing needs and help local health departments assess and manage outbreaks. This additional testing capacity is particularly germane for smaller cities and rural regions that would otherwise be unable to meet the testing demand.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by a Go Virginia Economic Resilience and Recovery Grant (20-GOVA-ERR-02A and 20-GOVA-ERR-02D), the Department of General Services of the Commonwealth of Virginia (DGS-201020-UVT), and funds from Virginia Tech, the Fralin Biomedical Research Institute at VTC, and the Fralin Life Sciences Institute. F.M.M. acknowledges support from NSF through CAREER-1652237 and the Virginia Tech Center for Earth and Environmental Nanotechnology "NanoEarth" (NNCI-1542100).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The testing protocol was submitted for Emergency Use Authorization from the Federal Drug Administration (EUA# 200383) and approved by the Virginia Tech Institutional Review Board (VT #20-852).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data related to the analysis in our manuscript is included as supplementary material and available to the scientific community.